Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A. Invests $3.28 Million in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)

Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A. bought a new position in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 59,204 shares of the company's stock, valued at approximately $3,278,000. Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A. owned 0.15% of Tarsus Pharmaceuticals as of its most recent SEC filing.

A number of other hedge funds have also added to or reduced their stakes in the stock. Crowley Wealth Management Inc. purchased a new stake in shares of Tarsus Pharmaceuticals in the fourth quarter worth about $25,000. R Squared Ltd bought a new position in shares of Tarsus Pharmaceuticals in the fourth quarter worth $53,000. Quarry LP purchased a new stake in shares of Tarsus Pharmaceuticals in the fourth quarter worth $166,000. HighTower Advisors LLC bought a new stake in Tarsus Pharmaceuticals during the fourth quarter valued at $207,000. Finally, Summit Investment Advisors Inc. grew its position in Tarsus Pharmaceuticals by 6.8% during the fourth quarter. Summit Investment Advisors Inc. now owns 3,848 shares of the company's stock worth $213,000 after buying an additional 244 shares in the last quarter. Hedge funds and other institutional investors own 90.01% of the company's stock.

Tarsus Pharmaceuticals Stock Up 0.0%

Shares of NASDAQ TARS traded up $0.01 during mid-day trading on Friday, hitting $42.98. 324,236 shares of the stock traded hands, compared to its average volume of 701,612. The company has a market cap of $1.81 billion, a price-to-earnings ratio of -11.28 and a beta of 0.94. The stock has a fifty day moving average price of $47.73 and a 200-day moving average price of $49.12. Tarsus Pharmaceuticals, Inc. has a 52 week low of $20.08 and a 52 week high of $57.28. The company has a debt-to-equity ratio of 0.30, a quick ratio of 5.38 and a current ratio of 5.42.

Tarsus Pharmaceuticals (NASDAQ:TARS - Get Free Report) last announced its earnings results on Thursday, May 1st. The company reported ($0.64) EPS for the quarter, beating analysts' consensus estimates of ($0.69) by $0.05. Tarsus Pharmaceuticals had a negative net margin of 103.64% and a negative return on equity of 55.86%. The firm had revenue of $78.34 million for the quarter, compared to analysts' expectations of $72.50 million. Research analysts anticipate that Tarsus Pharmaceuticals, Inc. will post -3.17 EPS for the current year.

Analyst Ratings Changes

Several analysts have weighed in on TARS shares. Guggenheim raised their price target on Tarsus Pharmaceuticals from $78.00 to $84.00 and gave the company a "buy" rating in a report on Friday, May 2nd. The Goldman Sachs Group boosted their price objective on shares of Tarsus Pharmaceuticals from $46.00 to $51.00 and gave the stock a "neutral" rating in a report on Monday, May 5th. Barclays lowered their target price on Tarsus Pharmaceuticals from $62.00 to $60.00 and set an "overweight" rating for the company in a research note on Wednesday, February 26th. Wall Street Zen cut shares of Tarsus Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Thursday. Finally, HC Wainwright reiterated a "buy" rating and set a $73.00 target price on shares of Tarsus Pharmaceuticals in a report on Wednesday, February 26th. Two investment analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, Tarsus Pharmaceuticals currently has a consensus rating of "Moderate Buy" and an average target price of $66.33.

Insiders Place Their Bets

In other Tarsus Pharmaceuticals news, insider Dianne C. Whitfield sold 2,137 shares of the business's stock in a transaction on Thursday, March 20th. The stock was sold at an average price of $50.11, for a total value of $107,085.07. Following the sale, the insider now directly owns 46,355 shares of the company's stock, valued at approximately $2,322,849.05. The trade was a 4.41% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, General Counsel Bryan Wahl sold 3,084 shares of the stock in a transaction on Thursday, March 20th. The stock was sold at an average price of $50.11, for a total value of $154,539.24. Following the completion of the sale, the general counsel now directly owns 51,712 shares in the company, valued at approximately $2,591,288.32. This represents a 5.63% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 32,542 shares of company stock worth $1,581,173. 8.25% of the stock is currently owned by company insiders.

Tarsus Pharmaceuticals Profile

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.